Hite Christopher: insider trades.
Hite Christopher reported 9 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 7 sales ($19.2M), across 1 company.
- Transactions
- 9
- Purchases (P)
- 0
- Sales (S)
- 7
- Companies
- 1
- Name as filed
- Hite Christopher
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Royalty Pharma plc (RPRX) | Officer · EVP & Chairman, Partnering | 9 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-22 | Royalty Pharma plc | S | 96,073 | $58.51 | 274,328 | Form 4 |
| 2026-09-22 | Royalty Pharma plc | S | 3,927 | $58.93 | 270,401 | Form 4 |
| 2026-08-19 | Royalty Pharma plc | G | 16,800 | $0 | 23,200 | Form 4 |
| 2026-08-18 | Royalty Pharma plc | S | 100,000 | $59.97 | 370,401 | Form 4 |
| 2026-08-05 | Royalty Pharma plc | A | 11,002 | $0 | 470,401 | Form 4 |
| 2026-06-30 | Royalty Pharma plc | S | 2,554 | $57.1 | 459,399 | Form 4 |
| 2026-06-30 | Royalty Pharma plc | S | 97,446 | $56.5 | 461,953 | Form 4 |
| 2026-06-30 | Royalty Pharma plc | S | 600 | $57.09 | 40,000 | Form 4 |
| 2026-06-30 | Royalty Pharma plc | S | 29,400 | $56.44 | 40,600 | Form 4 |
Questions
What stock did Hite Christopher buy or sell?
Hite Christopher reported 9 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 7 sales ($19.2M), across 1 company.
Is Hite Christopher the same person as other filers with this name?
This page covers SEC CIK 1814238 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/hite-christopher-1814238.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.